Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Queensland Health
Moodys
Cantor Fitzgerald
Deloitte
US Department of Justice

Generated: May 21, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,562,861

« Back to Dashboard

Which drugs does patent 6,562,861 protect, and when does it expire?

Patent 6,562,861 protects RAPIVAB and is included in one NDA.

This patent has twenty-eight patent family members in twenty-two countries.

Summary for Patent: 6,562,861
Title: Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors
Abstract:##STR1## Compounds I-III wherein U is CH, O, or S; Z is mono- or di-substituted carbon; R is (CH2)nCO2H, (CH2)nSO3H, (CH2)nPO3H2, (CH2)nNO2, CH(SCH3)3, esters; R1 is H, hydroxyalkyl, aminoalkyl, alkoxyalkyl; RR1 is O; n is 0-4; R2, R3 is H, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkyl; R4 is (CH2)nOH, (CH2)nNH2, substituted alkyl were prepd. as neuraminidase inhibitors. Thus, (1R,3R,4R,1'S)-(-)-(1'-acetylamino-2 '-ethyl)butyl-4-(aminoimino)methylaminocyclopentan-1-carboxylic acid was prepd. and tested in vitro as neuraminidase inhibitor (IC50<1.mu.M).
Inventor(s): Babu; Yarlagadda S. (Birmingham, AL), Chand; Pooran (Birmingham, AL), Montgomery; John A. (Birmingham, AL)
Assignee: BioCryst Pharmaceuticals, Inc. (Birmingham, AL)
Application Number:09/555,131
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 6,562,861
Patent Claim Types:
see list of patent claims
Compound; Use; Composition;

Drugs Protected by US Patent 6,562,861

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Biocryst RAPIVAB peramivir SOLUTION;INTRAVENOUS 206426-001 Dec 19, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,562,861

PCT Information
PCT FiledDecember 17, 1998PCT Application Number:PCT/US98/26871
PCT Publication Date:July 08, 1999PCT Publication Number: WO99/33781

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Chubb
Fuji
Chinese Patent Office
McKesson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.